There will be only 9,457 diagnosed prevalent cases of ES in 2023 in the 16 countries covered in GlobalData's epidemiology forecast for ES.
There are currently 11 marketed drugs for ES, the majority of which are DNA synthesis inhibitors.
R&D activity in ES is very strong in mid-stage, with 32 drugs in Phase II of development.
Clinical trial activity in ES was substantial during the past 10 years with 193 trials conducted overall.
Partnerships were the most common deal type executed globally in the ES space.

Scope

GlobalData's Ewing Sarcoma: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

Disease Landscape
Disease Overview
Epidemiology Overview
Treatment Overview
Marketed Products Assessment
Breakdown by Route of Administration
Product Profiles with Sales Forecast
Pricing and Reimbursement Assessment
Annual Therapy Cost
Time to Pricing and Time to Reimbursement
Pipeline Assessment
Breakdown by Development Stage, Molecule Type, Route of Administration
Product Profiles with Sales Forecast
Late-to-mid-stage Pipeline Drugs
Phase Transition Success Rate and Likelihood of Approval
Clinical Trials Assessment
Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
Enrolment Analytics, Site Analytics, Feasibility Analysis
Deals Landscape
Mergers, Acquisitions, and Strategic Alliances by Region
Overview of Recent Deals
Commercial Assessment
Key Market Players
Future Market Catalysts

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the Ewing Sarcoma market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Ewing Sarcoma market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Product Code: GDHC119CL

1 Preface

1.1 Contents
1.2 Report Scope
1.3 List of Tables and Figures
1.4 Abbreviations

2 Key Findings

3 Disease Landscape

3.1 Disease Overview
3.2 Epidemiology Overview
3.3 Treatment Overview

4 Marketed Drugs Assessment

4.1 Leading Marketed Drugs
4.2 Overview by Mechanism of Action
4.3 Overview by Route of Administration
4.4 Marketed Drugs Profiles and Sales Forecasts

5 Pricing and Reimbursement Assessment

5.1 Annual Therapy Cost
5.2 Time to Pricing and Reimbursement

6 Pipeline Drugs Assessment

6.1 Phase III Pipeline Drugs
6.2 Overview by Development Stage
6.3 Overview by Molecule Type
6.4 Overview by Mechanism of Action
6.5 Overview by Route of Administration
6.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
6.7 Therapy Area and Indication-specific PTSR and LoA